Figure 5
Figure 5. MYHIIA siRNA treatment removes most cellular staining by CLL mAb with stereotypic IGHV1-69, IGHD3-16, and IGHJ3 rearrangements. (A) Immunoblot of SNB19 cell extracts either untreated or after transfection with MYHIIA siRNA or Lipofectamine 2000 alone. Top part of membrane containing high MW proteins (> 75 kDa) was probed with anti-MYHIIA, and the lower part with low MW proteins was probed with anti-alpha-tubulin. MYHIIA siRNA reduced MYHIIA protein levels by 99.6% relative to Lipofectamine 2000 alone. Lipofectamine 2000 alone (Control) or siRNA-transfected SNB19 cells were stained with CLL068 antibody (green) and (B) anti-MYHIIA antibody (red) or (C) phalloidin stained F-actin (red). Cells were visualized by confocal microscopy separately and merged together.

MYHIIA siRNA treatment removes most cellular staining by CLL mAb with stereotypic IGHV1-69, IGHD3-16, and IGHJ3 rearrangements. (A) Immunoblot of SNB19 cell extracts either untreated or after transfection with MYHIIA siRNA or Lipofectamine 2000 alone. Top part of membrane containing high MW proteins (> 75 kDa) was probed with anti-MYHIIA, and the lower part with low MW proteins was probed with anti-alpha-tubulin. MYHIIA siRNA reduced MYHIIA protein levels by 99.6% relative to Lipofectamine 2000 alone. Lipofectamine 2000 alone (Control) or siRNA-transfected SNB19 cells were stained with CLL068 antibody (green) and (B) anti-MYHIIA antibody (red) or (C) phalloidin stained F-actin (red). Cells were visualized by confocal microscopy separately and merged together.

Close Modal

or Create an Account

Close Modal
Close Modal